OTCMKTS:OPHLF Ono Pharmaceutical (OPHLF) Stock Price, News & Analysis $10.95 -0.16 (-1.40%) As of 12:39 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Ono Pharmaceutical Stock (OTCMKTS:OPHLF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ono Pharmaceutical alerts:Sign Up Key Stats Today's Range$10.95▼$10.9550-Day Range$9.33▼$11.2152-Week Range$9.20▼$16.05Volume803 shsAverage Volume7,228 shsMarket Capitalization$5.14 billionP/E Ratio17.65Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan. Read More Receive OPHLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address OPHLF Stock News HeadlinesOno Pharmaceutical Co., Ltd. (OPHLF) Q1 FY2025 Earnings Call TranscriptAugust 3, 2025 | seekingalpha.comPharma company announces it will lay off 83 Boston-area employeesApril 30, 2025 | msn.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.August 8 at 2:00 AM | Weiss Ratings (Ad)Ono Pharmaceutical Enhances Governance and Diversity InitiativesMarch 24, 2025 | tipranks.comOno earmarks $940m to gain rare blood cancer therapy from IonisMarch 12, 2025 | msn.comOno Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology AreaDecember 5, 2024 | tmcnet.comNectar Classic Hybrid Mattress review 2024September 24, 2024 | fortune.comThe best Plank mattresses of 2024, tested and reviewedSeptember 24, 2024 | fortune.comSee More Headlines OPHLF Stock Analysis - Frequently Asked Questions How have OPHLF shares performed this year? Ono Pharmaceutical's stock was trading at $9.60 at the beginning of the year. Since then, OPHLF shares have increased by 14.0% and is now trading at $10.9450. How were Ono Pharmaceutical's earnings last quarter? Ono Pharmaceutical Co. (OTCMKTS:OPHLF) posted its quarterly earnings results on Monday, August, 4th. The company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.34 by $0.08. The company earned $886.27 million during the quarter, compared to the consensus estimate of $827.29 million. Ono Pharmaceutical had a trailing twelve-month return on equity of 5.49% and a net margin of 8.75%. How do I buy shares of Ono Pharmaceutical? Shares of OPHLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/04/2025Today8/08/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:OPHLF CIK940821 Webwww.ono.co.jp Phone(166) 263-5670Fax816-6263-2950Employees3,853Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.62 Trailing P/E Ratio17.65 Forward P/E RatioN/A P/E GrowthN/ANet Income$330.31 million Net Margins8.75% Pretax Margin12.19% Return on Equity5.49% Return on Assets4.12% Debt Debt-to-Equity Ratio0.13 Current Ratio3.07 Quick Ratio2.56 Sales & Book Value Annual Sales$3.20 billion Price / Sales1.61 Cash Flow$1.06 per share Price / Cash Flow10.30 Book Value$11.07 per share Price / Book0.99Miscellaneous Outstanding Shares469,708,000Free FloatN/AMarket Cap$5.14 billion OptionableNot Optionable Beta0.49 10 Stocks Set to Soar in Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:OPHLF) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ono Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ono Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.